5 📄 Overview A comprehensive platform designed for payers to manage GLP-1 cohorts, integrating patient data from SaMDs (adherence, side effects, outcomes), EHRs, and claims data. It enables performance-based contracting with providers or manufacturers, tying reimbursement to achieved clinical outcomes (e.g., sustained weight loss, HbA1c reduction, reduction in comorbidities). The platform would provide dashboards for population health management and risk stratification. Key technologies: 👤 Target users: 👍 Benefits Demonstrated ROI for GLP-1 therapy to payers • Incentivized high-quality care and adherence from providers • Reduced overall healthcare costs by preventing complications • Improved population health management for metabolic diseases Use bullets or new lines. 👎 Challenges Achieving true data interoperability across diverse systems • Defining and agreeing upon meaningful, measurable outcome metrics • Complex contracting and legal frameworks for value-based agreements • Ensuring data privacy and compliance across multiple stakeholders 📋 Regulatory & Validation This platform itself isn't a SaMD but aggregates and analyzes data from various sources, including potentially SaMDs. It requires strict adherence to data privacy regulations (HIPAA, GDPR) and robust security protocols. Any decision support for clinical management would need separate SaMD classification.